100.50Open100.50Pre Close0 Volume0 Open Interest350.00Strike Price0.00Turnover0.00%IV-2.99%PremiumJan 17, 2025Expiry Date107.74Intrinsic Value100Multiplier24DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.41Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet